This research report focuses on the Clinical Next Generation Sequencing (NGS) Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.
TABLE OF CONTENTS
1 Report Overview
- 1.1 Study Scope
- 1.2 Market Analysis by Type
- 1.2.1 Global Clinical Next Generation Sequencing (NGS) Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
- 1.2.2 Sequencing by Synthesis (SBS)
- 1.2.3 Nanopore Sequencing
- 1.2.4 Single-Molecule Real-Time (SMRT) Sequencing
- 1.2.5 Others
- 1.3 Market by Application
- 1.3.1 Global Clinical Next Generation Sequencing (NGS) Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
- 1.3.2 Diagnostics
- 1.3.3 Drug Discovery & Designing
- 1.3.4 Medical Research
- 1.3.5 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Clinical Next Generation Sequencing (NGS) Market Perspective (2018-2029)
- 2.2 Global Clinical Next Generation Sequencing (NGS) Growth Trends by Region
- 2.2.1 Clinical Next Generation Sequencing (NGS) Market Size by Region: 2018 VS 2022 VS 2029
- 2.2.2 Clinical Next Generation Sequencing (NGS) Historic Market Size by Region (2018-2023)
- 2.2.3 Clinical Next Generation Sequencing (NGS) Forecasted Market Size by Region (2024-2029)
- 2.3 Clinical Next Generation Sequencing (NGS) Market Dynamics
- 2.3.1 Clinical Next Generation Sequencing (NGS) Industry Trends
- 2.3.2 Clinical Next Generation Sequencing (NGS) Market Drivers
- 2.3.3 Clinical Next Generation Sequencing (NGS) Market Challenges
- 2.3.4 Clinical Next Generation Sequencing (NGS) Market Restraints
3 Competition Landscape by Key Players
- 3.1 Global Revenue Clinical Next Generation Sequencing (NGS) by Players
- 3.1.1 Global Clinical Next Generation Sequencing (NGS) Revenue by Players (2018-2023)
- 3.1.2 Global Clinical Next Generation Sequencing (NGS) Revenue Market Share by Players (2018-2023)
- 3.2 Global Clinical Next Generation Sequencing (NGS) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.3 Global Key Players of Clinical Next Generation Sequencing (NGS), Ranking by Revenue, 2021 VS 2022 VS 2023
- 3.4 Global Clinical Next Generation Sequencing (NGS) Market Concentration Ratio
- 3.4.1 Global Clinical Next Generation Sequencing (NGS) Market Concentration Ratio (CR5 and HHI)
- 3.4.2 Global Top 10 and Top 5 Companies by Clinical Next Generation Sequencing (NGS) Revenue in 2022
- 3.5 Global Key Players of Clinical Next Generation Sequencing (NGS) Head office and Area Served
- 3.6 Global Key Players of Clinical Next Generation Sequencing (NGS), Product and Application
- 3.7 Global Key Players of Clinical Next Generation Sequencing (NGS), Date of Enter into This Industry
- 3.8 Mergers & Acquisitions, Expansion Plans
4 Clinical Next Generation Sequencing (NGS) Breakdown Data by Type
- 4.1 Global Clinical Next Generation Sequencing (NGS) Historic Market Size by Type (2018-2023)
- 4.2 Global Clinical Next Generation Sequencing (NGS) Forecasted Market Size by Type (2024-2029)
5 Clinical Next Generation Sequencing (NGS) Breakdown Data by Application
- 5.1 Global Clinical Next Generation Sequencing (NGS) Historic Market Size by Application (2018-2023)
- 5.2 Global Clinical Next Generation Sequencing (NGS) Forecasted Market Size by Application (2024-2029)
6 North America
- 6.1 North America Clinical Next Generation Sequencing (NGS) Market Size (2018-2029)
- 6.2 North America Clinical Next Generation Sequencing (NGS) Market Size by Type
- 6.2.1 North America Clinical Next Generation Sequencing (NGS) Market Size by Type (2018-2023)
- 6.2.2 North America Clinical Next Generation Sequencing (NGS) Market Size by Type (2024-2029)
- 6.2.3 North America Clinical Next Generation Sequencing (NGS) Market Share by Type (2018-2029)
- 6.3 North America Clinical Next Generation Sequencing (NGS) Market Size by Application
- 6.3.1 North America Clinical Next Generation Sequencing (NGS) Market Size by Application (2018-2023)
- 6.3.2 North America Clinical Next Generation Sequencing (NGS) Market Size by Application (2024-2029)
- 6.3.3 North America Clinical Next Generation Sequencing (NGS) Market Share by Application (2018-2029)
- 6.4 North America Clinical Next Generation Sequencing (NGS) Market Size by Country
- 6.4.1 North America Clinical Next Generation Sequencing (NGS) Market Size by Country: 2018 VS 2022 VS 2029
- 6.4.2 North America Clinical Next Generation Sequencing (NGS) Market Size by Country (2018-2023)
- 6.4.3 North America Clinical Next Generation Sequencing (NGS) Market Size by Country (2024-2029)
- 6.4.4 United States
- 6.4.5 Canada
7 Europe
- 7.1 Europe Clinical Next Generation Sequencing (NGS) Market Size (2018-2029)
- 7.2 Europe Clinical Next Generation Sequencing (NGS) Market Size by Type
- 7.2.1 Europe Clinical Next Generation Sequencing (NGS) Market Size by Type (2018-2023)
- 7.2.2 Europe Clinical Next Generation Sequencing (NGS) Market Size by Type (2024-2029)
- 7.2.3 Europe Clinical Next Generation Sequencing (NGS) Market Share by Type (2018-2029)
- 7.3 Europe Clinical Next Generation Sequencing (NGS) Market Size by Application
- 7.3.1 Europe Clinical Next Generation Sequencing (NGS) Market Size by Application (2018-2023)
- 7.3.2 Europe Clinical Next Generation Sequencing (NGS) Market Size by Application (2024-2029)
- 7.3.3 Europe Clinical Next Generation Sequencing (NGS) Market Share by Application (2018-2029)
- 7.4 Europe Clinical Next Generation Sequencing (NGS) Market Size by Country
- 7.4.1 Europe Clinical Next Generation Sequencing (NGS) Market Size by Country: 2018 VS 2022 VS 2029
- 7.4.2 Europe Clinical Next Generation Sequencing (NGS) Market Size by Country (2018-2023)
- 7.4.3 Europe Clinical Next Generation Sequencing (NGS) Market Size by Country (2024-2029)
- 7.4.3 Germany
- 7.4.4 France
- 7.4.5 U.K.
- 7.4.6 Italy
- 7.4.7 Russia
- 7.4.8 Nordic Countries
8 China
- 8.1 China Clinical Next Generation Sequencing (NGS) Market Size (2018-2029)
- 8.2 China Clinical Next Generation Sequencing (NGS) Market Size by Type
- 8.2.1 China Clinical Next Generation Sequencing (NGS) Market Size by Type (2018-2023)
- 8.2.2 China Clinical Next Generation Sequencing (NGS) Market Size by Type (2024-2029)
- 8.2.3 China Clinical Next Generation Sequencing (NGS) Market Share by Type (2018-2029)
- 8.3 China Clinical Next Generation Sequencing (NGS) Market Size by Application
- 8.3.1 China Clinical Next Generation Sequencing (NGS) Market Size by Application (2018-2023)
- 8.3.2 China Clinical Next Generation Sequencing (NGS) Market Size by Application (2024-2029)
- 8.3.3 China Clinical Next Generation Sequencing (NGS) Market Share by Application (2018-2029)
9 Asia (excluding China)
- 9.1 Asia Clinical Next Generation Sequencing (NGS) Market Size (2018-2029)
- 9.2 Asia Clinical Next Generation Sequencing (NGS) Market Size by Type
- 9.2.1 Asia Clinical Next Generation Sequencing (NGS) Market Size by Type (2018-2023)
- 9.2.2 Asia Clinical Next Generation Sequencing (NGS) Market Size by Type (2024-2029)
- 9.2.3 Asia Clinical Next Generation Sequencing (NGS) Market Share by Type (2018-2029)
- 9.3 Asia Clinical Next Generation Sequencing (NGS) Market Size by Application
- 9.3.1 Asia Clinical Next Generation Sequencing (NGS) Market Size by Application (2018-2023)
- 9.3.2 Asia Clinical Next Generation Sequencing (NGS) Market Size by Application (2024-2029)
- 9.3.3 Asia Clinical Next Generation Sequencing (NGS) Market Share by Application (2018-2029)
- 9.4 Asia Clinical Next Generation Sequencing (NGS) Market Size by Region
- 9.4.1 Asia Clinical Next Generation Sequencing (NGS) Market Size by Region: 2018 VS 2022 VS 2029
- 9.4.2 Asia Clinical Next Generation Sequencing (NGS) Market Size by Region (2018-2023)
- 9.4.3 Asia Clinical Next Generation Sequencing (NGS) Market Size by Region (2024-2029)
- 9.4.4 Japan
- 9.4.5 South Korea
- 9.4.6 China Taiwan
- 9.4.7 Southeast Asia
- 9.4.8 India
- 9.4.9 Australia
10 Middle East, Africa, and Latin America
- 10.1 Middle East, Africa, and Latin America Clinical Next Generation Sequencing (NGS) Market Size (2018-2029)
- 10.2 Middle East, Africa, and Latin America Clinical Next Generation Sequencing (NGS) Market Size by Type
- 10.2.1 Middle East, Africa, and Latin America Clinical Next Generation Sequencing (NGS) Market Size by Type (2018-2023)
- 10.2.2 Middle East, Africa, and Latin America Clinical Next Generation Sequencing (NGS) Market Size by Type (2024-2029)
- 10.2.3 Middle East, Africa, and Latin America Clinical Next Generation Sequencing (NGS) Market Share by Type (2018-2029)
- 10.3 Middle East, Africa, and Latin America Clinical Next Generation Sequencing (NGS) Market Size by Application
- 10.3.1 Middle East, Africa, and Latin America Clinical Next Generation Sequencing (NGS) Market Size by Application (2018-2023)
- 10.3.2 Middle East, Africa, and Latin America Clinical Next Generation Sequencing (NGS) Market Size by Application (2024-2029)
- 10.3.3 Middle East, Africa, and Latin America Clinical Next Generation Sequencing (NGS) Market Share by Application (2018-2029)
- 10.4 Middle East, Africa, and Latin America Clinical Next Generation Sequencing (NGS) Market Size by Country
- 10.4.1 Middle East, Africa, and Latin America Clinical Next Generation Sequencing (NGS) Market Size by Country: 2018 VS 2022 VS 2029
- 10.4.2 Middle East, Africa, and Latin America Clinical Next Generation Sequencing (NGS) Market Size by Country (2018-2023)
- 10.4.3 Middle East, Africa, and Latin America Clinical Next Generation Sequencing (NGS) Market Size by Country (2024-2029)
- 10.4.4 Brazil
- 10.4.5 Mexico
- 10.4.6 Turkey
- 10.4.7 Saudi Arabia
- 10.4.8 Israel
- 10.4.9 GCC Countries
11 Key Players Profiles
- 11.1 Agilent Technologies
- 11.1.1 Agilent Technologies Company Details
- 11.1.2 Agilent Technologies Business Overview
- 11.1.3 Agilent Technologies Clinical Next Generation Sequencing (NGS) Introduction
- 11.1.4 Agilent Technologies Revenue in Clinical Next Generation Sequencing (NGS) Business (2018-2023)
- 11.1.5 Agilent Technologies Recent Developments
- 11.2 Illumina
- 11.2.1 Illumina Company Details
- 11.2.2 Illumina Business Overview
- 11.2.3 Illumina Clinical Next Generation Sequencing (NGS) Introduction
- 11.2.4 Illumina Revenue in Clinical Next Generation Sequencing (NGS) Business (2018-2023)
- 11.2.5 Illumina Recent Developments
- 11.3 Thermo Fisher Scientific
- 11.3.1 Thermo Fisher Scientific Company Details
- 11.3.2 Thermo Fisher Scientific Business Overview
- 11.3.3 Thermo Fisher Scientific Clinical Next Generation Sequencing (NGS) Introduction
- 11.3.4 Thermo Fisher Scientific Revenue in Clinical Next Generation Sequencing (NGS) Business (2018-2023)
- 11.3.5 Thermo Fisher Scientific Recent Developments
- 11.4 Eurofins Scientific
- 11.4.1 Eurofins Scientific Company Details
- 11.4.2 Eurofins Scientific Business Overview
- 11.4.3 Eurofins Scientific Clinical Next Generation Sequencing (NGS) Introduction
- 11.4.4 Eurofins Scientific Revenue in Clinical Next Generation Sequencing (NGS) Business (2018-2023)
- 11.4.5 Eurofins Scientific Recent Developments
- 11.5 BGI Group
- 11.5.1 BGI Group Company Details
- 11.5.2 BGI Group Business Overview
- 11.5.3 BGI Group Clinical Next Generation Sequencing (NGS) Introduction
- 11.5.4 BGI Group Revenue in Clinical Next Generation Sequencing (NGS) Business (2018-2023)
- 11.5.5 BGI Group Recent Developments
- 11.6 Qiagen
- 11.6.1 Qiagen Company Details
- 11.6.2 Qiagen Business Overview
- 11.6.3 Qiagen Clinical Next Generation Sequencing (NGS) Introduction
- 11.6.4 Qiagen Revenue in Clinical Next Generation Sequencing (NGS) Business (2018-2023)
- 11.6.5 Qiagen Recent Developments
- 11.7 Roche Diagnostics
- 11.7.1 Roche Diagnostics Company Details
- 11.7.2 Roche Diagnostics Business Overview
- 11.7.3 Roche Diagnostics Clinical Next Generation Sequencing (NGS) Introduction
- 11.7.4 Roche Diagnostics Revenue in Clinical Next Generation Sequencing (NGS) Business (2018-2023)
- 11.7.5 Roche Diagnostics Recent Developments
- 11.8 Bio-Rad
- 11.8.1 Bio-Rad Company Details
- 11.8.2 Bio-Rad Business Overview
- 11.8.3 Bio-Rad Clinical Next Generation Sequencing (NGS) Introduction
- 11.8.4 Bio-Rad Revenue in Clinical Next Generation Sequencing (NGS) Business (2018-2023)
- 11.8.5 Bio-Rad Recent Developments
- 11.9 Congenica
- 11.9.1 Congenica Company Details
- 11.9.2 Congenica Business Overview
- 11.9.3 Congenica Clinical Next Generation Sequencing (NGS) Introduction
- 11.9.4 Congenica Revenue in Clinical Next Generation Sequencing (NGS) Business (2018-2023)
- 11.9.5 Congenica Recent Developments
- 11.10 Theragen Etex
- 11.10.1 Theragen Etex Company Details
- 11.10.2 Theragen Etex Business Overview
- 11.10.3 Theragen Etex Clinical Next Generation Sequencing (NGS) Introduction
- 11.10.4 Theragen Etex Revenue in Clinical Next Generation Sequencing (NGS) Business (2018-2023)
- 11.10.5 Theragen Etex Recent Developments
- 11.11 PerkinElmer
- 11.11.1 PerkinElmer Company Details
- 11.11.2 PerkinElmer Business Overview
- 11.11.3 PerkinElmer Clinical Next Generation Sequencing (NGS) Introduction
- 11.11.4 PerkinElmer Revenue in Clinical Next Generation Sequencing (NGS) Business (2018-2023)
- 11.11.5 PerkinElmer Recent Developments
- 11.12 Partek
- 11.12.1 Partek Company Details
- 11.12.2 Partek Business Overview
- 11.12.3 Partek Clinical Next Generation Sequencing (NGS) Introduction
- 11.12.4 Partek Revenue in Clinical Next Generation Sequencing (NGS) Business (2018-2023)
- 11.12.5 Partek Recent Developments
- 11.13 Oxford Nanopore Technologies
- 11.13.1 Oxford Nanopore Technologies Company Details
- 11.13.2 Oxford Nanopore Technologies Business Overview
- 11.13.3 Oxford Nanopore Technologies Clinical Next Generation Sequencing (NGS) Introduction
- 11.13.4 Oxford Nanopore Technologies Revenue in Clinical Next Generation Sequencing (NGS) Business (2018-2023)
- 11.13.5 Oxford Nanopore Technologies Recent Developments
- 11.14 Pacific Biosciences of California
- 11.14.1 Pacific Biosciences of California Company Details
- 11.14.2 Pacific Biosciences of California Business Overview
- 11.14.3 Pacific Biosciences of California Clinical Next Generation Sequencing (NGS) Introduction
- 11.14.4 Pacific Biosciences of California Revenue in Clinical Next Generation Sequencing (NGS) Business (2018-2023)
- 11.14.5 Pacific Biosciences of California Recent Developments
- 11.15 Golden Helix
- 11.15.1 Golden Helix Company Details
- 11.15.2 Golden Helix Business Overview
- 11.15.3 Golden Helix Clinical Next Generation Sequencing (NGS) Introduction
- 11.15.4 Golden Helix Revenue in Clinical Next Generation Sequencing (NGS) Business (2018-2023)
- 11.15.5 Golden Helix Recent Developments
- 11.16 BioDatomics
- 11.16.1 BioDatomics Company Details
- 11.16.2 BioDatomics Business Overview
- 11.16.3 BioDatomics Clinical Next Generation Sequencing (NGS) Introduction
- 11.16.4 BioDatomics Revenue in Clinical Next Generation Sequencing (NGS) Business (2018-2023)
- 11.16.5 BioDatomics Recent Developments
- 11.17 PierianDx
- 11.17.1 PierianDx Company Details
- 11.17.2 PierianDx Business Overview
- 11.17.3 PierianDx Clinical Next Generation Sequencing (NGS) Introduction
- 11.17.4 PierianDx Revenue in Clinical Next Generation Sequencing (NGS) Business (2018-2023)
- 11.17.5 PierianDx Recent Developments
- 11.18 DNAStar
- 11.18.1 DNAStar Company Details
- 11.18.2 DNAStar Business Overview
- 11.18.3 DNAStar Clinical Next Generation Sequencing (NGS) Introduction
- 11.18.4 DNAStar Revenue in Clinical Next Generation Sequencing (NGS) Business (2018-2023)
- 11.18.5 DNAStar Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
- 13.1 Research Methodology
- 13.1.1 Methodology/Research Approach
- 13.1.2 Data Source
- 13.2 Disclaimer
- 13.3 Author Details